MMP-9 expression in meningiomas: A prognostic marker for recurrence risk?

Journal of Neuro-Oncology

Volumn 102, Issue 2, 2011, Pages 189-196

  Barresi, V ^a   Vitarelli, E ^a   Tuccari, G ^a   Barresi, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Angiogenesis; Meningioma; MMP 9; MVD; Recurrence; VEGF

Indexed keywords

GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; MICROVASCULATURE; NEUROSURGERY; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 9; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79953721950     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0312-8     Document Type: Article

References (31)

1. Perry A, Stafford SL, Scheithauer BW, Lohse CM, Wollan PC (1999) "Malignancy" in meningiomas: a clinico-pathological study of 116 patients with grading implications. Cancer 85:2046-2056
2. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22-39
3. Kamitani H, Masuzawa H, Kanazawa I, Kubo T (2001) Recurrence of convexity meningiomas: tumour cells in the arachnoid membrane. Surg Neurol 56:228-235 (Pubitemid 33101072)
4. Kinjo T, al-Mefty O, Kanaan I (1993) Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33:394-399
5. Chang C, Werb Z (2001) The many faces of metalloproteinases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11:S37-S43
6. Mizoue T, Kawamoto H, Arita K, Tominaga A, Kurisu K (1999) Secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by meningiomas detected by cell immunoblot analysis. Acta Neurochir 141:481-486 (Pubitemid 29240591)
7. Nordqvist AC, Smurawa H, Mathiesen T (2001) Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 95:839-844 (Pubitemid 33043358)
8. Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, Jung HW (2002) Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol 60:235-245 (Pubitemid 35439178)
9. Rooprai HK, van Meter TE, Robinson SD, King A, Rucklidge GJ, Pilkington GJ (2003) Expression of MMP-2 and -9 in short-term cultures of meningioma: influence of histological subtype. Int J Mol Med 12:977-981
10. Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S (2004) Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 66:29-37 (Pubitemid 38259817)
11. von Randow AJ, Schindler S, Tews DS (2006) Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol Res Pract 202:365-372
12. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A (2008) Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol 89:73-87
13. Bellon G, Caulet T, Cam Y, Pluot M, Poulin M, Pytlinska M, Bernard MH (1985) Immunohistochemical localisation of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol 66:245-252 (Pubitemid 15122193)
14. Ng HK, Wong AT (1993) Expression of epithelial and extracellular matrix protein markers in meningiomas. Histopathology 22:113-125 (Pubitemid 23067131)
15. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744
17. Ebrahem Q, Chaurasia SS, Vasanji A, Qi JH, Klenotic PA, Cutler A, Asosingh K, Erzurum S, Anand-Apte B (2010) Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 176:496-503
18. Perry A, Louis DN, Scheithauer BW (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK et al (eds) WHO Classification of Tumors of the Central Nervous System. IARCC press, Lyon, pp 164-172
19. Barresi V, Cerasoli S, Vitarelli E, Tuccari G (2007) Density of microvessel positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114:147-156 (Pubitemid 47103525)
20. Barresi V, Cerasoli S, Tuccari G (2008) Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 28:472-478
21. Barresi V, Vitarelli E, Cerasoli S (2009) Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. Virchows Arch 454:563-571
22. Barresi V, Tuccari G (2010) Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology. doi:10.1111/j.1440-1789.2010.01105.x
23. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82:2262-2269 (Pubitemid 28240835)
24. Ennis BW, Matrisian LM (1994) Matrix degrading metalloproteinases. J Neurooncol 18:105-109 (Pubitemid 24216045)
25. Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461-469
26. Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS (2007) RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol 31:1039-1050
27. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267: 10931-10934
28. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25 (Pubitemid 27076453)
29. Christov C, Lechapt-Zalcman E, Adle-Biassette H, Nachev S, Gherardi RK (1999) Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas. Acta Neuropathol 98:414-420 (Pubitemid 29440689)
30. Zhang X, Yamashita M, Uetsuki H, Kakehi Y (2002) Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 9:509-514 (Pubitemid 35365569)
31. Das A, Tan WL, Smith D (2003) Expression of extracellular matrix markers in benign meningiomas. Neuropathology 23: 275-281 (Pubitemid 38004859)